Last updated on January 2020

AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH


Brief description of study

The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with NASH.

Detailed Study Description

The AURORA study will be conducted in 2 parts. Part 1 will examine the surrogate endpoint of improvement in fibrosis of at least 1 stage (nonalcoholic steatohepatitis clinical research network [NASH CRN]) and no worsening of steatohepatitis at Month 12. Subjects from Part 1 will continue into Part 2 and additional subjects will be newly randomized in Part 2 to determine long-term clinical outcomes composed of histopathologic progression to cirrhosis, liver-related clinical outcomes, and all-cause mortality.

Clinical Study Identifier: NCT03028740

Find a site near you

Start Over

Digestive Disease Associates

Catonsville, MD United States
  Connect »

Gastro Center of Maryland

Columbia, MD United States
7.06miles
  Connect »

Mercy Medical Center

Baltimore, MD United States
7.25miles
  Connect »

Johns Hopkins University

Baltimore, MD United States
8.71miles
  Connect »

Woodholme Gastroenterology - Severn

Glen Burnie, MD United States
9.98miles
  Connect »